发现3-(4-氨磺酰基萘基)吡唑并[1,5-a]嘧啶作为强效且选择性的ALK2抑制剂。
Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors.
作者信息
Jiang Jian-Kang, Huang Xiuli, Shamim Khalida, Patel Paresma R, Lee Arthur, Wang Amy Q, Nguyen Kimloan, Tawa Gregory, Cuny Gregory D, Yu Paul B, Zheng Wei, Xu Xin, Sanderson Philip, Huang Wenwei
机构信息
National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Bethesda, MD 20892-3370, USA.
National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Bethesda, MD 20892-3370, USA.
出版信息
Bioorg Med Chem Lett. 2018 Nov 1;28(20):3356-3362. doi: 10.1016/j.bmcl.2018.09.006. Epub 2018 Sep 6.
Abstract
The pyrazolo[1,5-a]pyrimidine LDN-193189 is a potent inhibitor of activin receptor-like kinase 2 (ALK2) but is nonselective for highly homologous ALK3 and shows only modest kinome selectivity. Herein, we describe the discovery of a novel series of potent and selective ALK2 inhibitors by replacing the quinolinyl with a 4-(sulfamoyl)naphthyl, yielding ALK2 inhibitors that exhibit not only excellent discrimination versus ALK3 but also high kinome selectivity. In addition, the optimized compound 23 demonstrates good ADME and in vivo pharmacokinetic properties.
摘要
吡唑并[1,5 - a]嘧啶类化合物LDN - 193189是激活素受体样激酶2（ALK2）的强效抑制剂，但对高度同源的ALK3无选择性，且在激酶组中仅表现出适度的选择性。在此，我们描述了通过用4 -（氨磺酰基）萘基取代喹啉基发现了一系列新型的强效且选择性的ALK2抑制剂，得到的ALK2抑制剂不仅对ALK3具有出色的区分性，而且在激酶组中具有高选择性。此外，优化后的化合物23表现出良好的吸收、分布、代谢和排泄（ADME）及体内药代动力学性质。
相似文献
1
Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors.
Bioorg Med Chem Lett. 2018 Nov 1;28(20):3356-3362. doi: 10.1016/j.bmcl.2018.09.006. Epub 2018 Sep 6.
2
Development of an ALK2-biased BMP type I receptor kinase inhibitor.
ACS Chem Biol. 2013;8(6):1291-302. doi: 10.1021/cb300655w. Epub 2013 Apr 30.
3
Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe.
Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52. doi: 10.1016/j.bmcl.2013.03.113. Epub 2013 Apr 11.
4
Discovery of highly potent and selective type I B-Raf kinase inhibitors.
Bioorg Med Chem Lett. 2009 Dec 1;19(23):6571-4. doi: 10.1016/j.bmcl.2009.10.030. Epub 2009 Oct 13.
5
Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 1.
Bioorg Med Chem Lett. 2011 Jan 1;21(1):467-70. doi: 10.1016/j.bmcl.2010.10.113. Epub 2010 Oct 27.
6
Novel bicyclic pyrazoles as potent ALK2 (R206H) inhibitors for the treatment of fibrodysplasia ossificans progressiva.
Bioorg Med Chem Lett. 2021 Apr 15;38:127858. doi: 10.1016/j.bmcl.2021.127858. Epub 2021 Feb 18.
7
ALK2 inhibitors display beneficial effects in preclinical models of mutant diffuse intrinsic pontine glioma.
Commun Biol. 2019 May 9;2:156. doi: 10.1038/s42003-019-0420-8. eCollection 2019.
8
2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2.
Bioorg Med Chem Lett. 2009 Dec 1;19(23):6529-33. doi: 10.1016/j.bmcl.2009.10.053. Epub 2009 Oct 24.
9
Discovery of pyrazolo[1,5-a]pyrimidine-based Pim inhibitors: a template-based approach.
Bioorg Med Chem Lett. 2013 Nov 15;23(22):6178-82. doi: 10.1016/j.bmcl.2013.08.110. Epub 2013 Sep 7.
10
Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 2.
Bioorg Med Chem Lett. 2011 Jan 1;21(1):471-4. doi: 10.1016/j.bmcl.2010.10.114. Epub 2010 Oct 28.
引用本文的文献
1
Advancements in mechanisms and drug treatments for fibrodysplasia ossificans progressiva.
J Zhejiang Univ Sci B. 2025 Apr 23;26(4):317-332. doi: 10.1631/jzus.B2300779.
2
Insights into Novel Arylazopyrazolo[1,5-]pyrimidines as Promising MurA Inhibitors and Antibiofilm Candidates: Design, Synthesis, Antimicrobial Evaluation, and Molecular Docking.
ACS Omega. 2025 Jan 24;10(4):4044-4056. doi: 10.1021/acsomega.4c10286. eCollection 2025 Feb 4.
3
Discovery of Conformationally Constrained ALK2 Inhibitors.
J Med Chem. 2024 Mar 28;67(6):4707-4725. doi: 10.1021/acs.jmedchem.3c02308. Epub 2024 Mar 18.
4
Small-Molecule Probes as Pharmacological Tools for the Bone Morphogenetic Protein Signaling Pathway.
ACS Pharmacol Transl Sci. 2023 Oct 27;6(11):1574-1599. doi: 10.1021/acsptsci.3c00170. eCollection 2023 Nov 10.
5
Recent Advances in ALK2 Inhibitors.
ACS Omega. 2021 Aug 6;6(32):20729-20734. doi: 10.1021/acsomega.1c02983. eCollection 2021 Aug 17.
6
Temperature-modulated selective C(sp)-H or C(sp)-H arylation through palladium catalysis.
Chem Sci. 2020 Sep 24;11(42):11461-11467. doi: 10.1039/d0sc02328k.
7
Discovery, synthesis and characterization of a series of 7-aryl-imidazo[1,2-a]pyridine-3-ylquinolines as activin-like kinase (ALK) inhibitors.
Bioorg Med Chem Lett. 2020 Sep 15;30(18):127418. doi: 10.1016/j.bmcl.2020.127418. Epub 2020 Jul 17.
8
Targeting ALK2: An Open Science Approach to Developing Therapeutics for the Treatment of Diffuse Intrinsic Pontine Glioma.
J Med Chem. 2020 May 14;63(9):4978-4996. doi: 10.1021/acs.jmedchem.0c00395. Epub 2020 May 5.
9
An efficient and targeted synthetic approach towards new highly substituted 6-amino-pyrazolo[1,5-a]pyrimidines with α-glucosidase inhibitory activity.
Sci Rep. 2020 Feb 13;10(1):2595. doi: 10.1038/s41598-020-59079-z.
10
Application of Drug Metabolism Studies in Chemical Structure Optimization for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP).
Front Pharmacol. 2019 Apr 24;10:234. doi: 10.3389/fphar.2019.00234. eCollection 2019.
本文引用的文献
1
Acute and chronic rapamycin use in patients with Fibrodysplasia Ossificans Progressiva: A report of two cases.
Bone. 2018 Apr;109:281-284. doi: 10.1016/j.bone.2017.12.011. Epub 2017 Dec 11.
2
Structural basis for the potent and selective binding of LDN-212854 to the BMP receptor kinase ALK2.
Bone. 2018 Apr;109:251-258. doi: 10.1016/j.bone.2017.09.004. Epub 2017 Sep 12.
3
Identification of novel ALK2 inhibitors and their effect on cancer cells.
Biochem Biophys Res Commun. 2017 Oct 7;492(1):121-127. doi: 10.1016/j.bbrc.2017.08.016. Epub 2017 Aug 4.
4
Activin-A enhances mTOR signaling to promote aberrant chondrogenesis in fibrodysplasia ossificans progressiva.
J Clin Invest. 2017 Sep 1;127(9):3339-3352. doi: 10.1172/JCI93521. Epub 2017 Jul 31.
5
Inhibitors of the bone morphogenetic protein (BMP) signaling pathway: a patent review (2008-2015).
Expert Opin Ther Pat. 2016 Oct;26(10):1115-1128. doi: 10.1080/13543776.2016.1217330. Epub 2016 Aug 4.
6
Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1(R206H) Fibrodysplasia Ossificans Progressiva (FOP) Mutation.
J Bone Miner Res. 2016 Sep;31(9):1666-75. doi: 10.1002/jbmr.2820. Epub 2016 Mar 12.
7
Neofunction of ACVR1 in fibrodysplasia ossificans progressiva.
Proc Natl Acad Sci U S A. 2015 Dec 15;112(50):15438-43. doi: 10.1073/pnas.1510540112. Epub 2015 Nov 30.
8
ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A.
Sci Transl Med. 2015 Sep 2;7(303):303ra137. doi: 10.1126/scitranslmed.aac4358.
9
A small molecule targeting ALK1 prevents Notch cooperativity and inhibits functional angiogenesis.
Angiogenesis. 2015 Apr;18(2):209-17. doi: 10.1007/s10456-014-9457-y. Epub 2015 Jan 4.
10
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
J Med Chem. 2014 Oct 9;57(19):7900-15. doi: 10.1021/jm501177w. Epub 2014 Sep 4.
Zotero 插件